Holen Sie sich die Stockscreener-App
9.36
3.43%
0.31
Handel nachbörslich:
9.39
0.03
+0.32%
Schlusskurs vom Vortag:
$9.05
Offen:
$9.12
24-Stunden-Volumen:
3.71M
Relative Volume:
0.81
Marktkapitalisierung:
$2.43B
Einnahmen:
$6.29B
Nettoeinkommen (Verlust:
$750.00M
KGV:
3.25
EPS:
2.88
Netto-Cashflow:
$586.00M
1W Leistung:
+7.34%
1M Leistung:
-5.84%
6M Leistung:
-42.65%
1J Leistung:
-53.87%
1-Tages-Spanne:
$9.00
$9.425
1-Wochen-Bereich:
$8.64
$9.425
52-Wochen-Spanne:
$8.01
$23.10
Organon Co Stock (OGN) Company Profile
Firmenname
Organon Co
Sektor
Telefon
551-430-6000
Adresse
30 HUDSON STREET, JERSEY CITY
Vergleichen Sie OGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
9.36 | 2.35B | 6.29B | 750.00M | 586.00M | 2.88 |
|
LLY
Lilly Eli Co
|
660.49 | 573.22B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
174.42 | 416.11B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
201.47 | 350.91B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
121.20 | 230.97B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
82.71 | 200.57B | 63.43B | 16.42B | 14.72B | 6.49 |
Organon Co Stock (OGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-09-06 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-11-03 | Herabstufung | Goldman | Buy → Neutral |
| 2023-09-21 | Eingeleitet | Barclays | Overweight |
| 2023-03-16 | Eingeleitet | Raymond James | Outperform |
| 2022-10-14 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-09-06 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-08-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-10-07 | Eingeleitet | Piper Sandler | Neutral |
| 2021-09-01 | Eingeleitet | BofA Securities | Buy |
| 2021-07-22 | Eingeleitet | Citigroup | Buy |
| 2021-06-15 | Eingeleitet | JP Morgan | Neutral |
| 2021-06-11 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-06-10 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
Organon Co Aktie (OGN) Neueste Nachrichten
NYSE: OGN Lawsuit Alert: Investors who lost money with Organon & Co. (NYSE: OGN) shares should contact the Shareholders Foundation - PR Newswire
Ex-Dividend Reminder: Cencora, Organon and Esquire Financial Holdings - Nasdaq
5 Must-Read Analyst Questions From Organon’s Q2 Earnings Call - Yahoo Finance
OGN Q2 Deep Dive: Flat Sales, Margin Pressure, and Strategic Shifts Highlight Quarter - Yahoo Finance
Organon's Valuation: Discounted Due to Structural Challenges - AInvest
Organon: Valuation Discount Offset By Structural Headwinds (NYSE:OGN) - Seeking Alpha
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know - MSN
Natixis Advisors LLC Has $778,000 Holdings in Organon & Co. (NYSE:OGN) - Defense World
Organon & Co. (OGN): Assessing Dividend Sustainability and Valuation Amid Earnings Pressures and Strategic Catalysts - AInvest
Read This Before Considering Organon & Co. (NYSE:OGN) For Its Upcoming US$0.02 Dividend - uk.finance.yahoo.com
Organon & Co. (OGN) Reports Q2 2025 Results - MSN
Organon Q2 Preview: What to expect? - MSN
Organon & Co. (NYSE:OGN) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Organon & Co. (NYSE:OGN) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year - Yahoo Finance
Organon & Co. Reports Q2 2025 Financial Results - The Globe and Mail
Organon & Co. Earnings Call: Resilience Amid Challenges - The Globe and Mail
Organon (OGN) Fiscal Q2 Revenue Beats 1% - AOL.com
Organon & Co. (OGN) Slashes 13.13% on Disappointing Earnings - MSN
Organon Q2 Earnings: It May Be Time To Desert This Sinking Ship (Downgrade) (NYSE:OGN) - Seeking Alpha
Endometriosis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine Biosciences - The Globe and Mail
Organon & Co. SEC 10-Q Report - TradingView
Organon & Co. (NYSE:OGN) Q2 2025 Earnings Call Transcript - Insider Monkey
Organon Reports Results for the Second Quarter Ended June 30, 2025 - BioSpace
Organon & Co (OGN) Q2 2025 Earnings Call Highlights: Navigating Challenges with Strategic Growth By GuruFocus - Investing.com Canada
Organon: Q2 Earnings Snapshot - Norwalk Hour
Organon raises 2025 revenue guidance by $100M amid Vtama ramp and debt reduction focus - MSN
Organon & Co To Go Ex-Dividend On August 15th, 2025 With 0.02 USD Dividend Per Share - 富途牛牛
Organon reports Q2 adjusted EPS $1.00, consensus 94c - TipRanks
Organon raises FY25 revenue view to $6.28B-$6.38B from $6.13B-$6.33B - TipRanks
OGN Shares Plunge: Lawsuit Drives Market Shock - StocksToTrade
Organon & Co. 2025 Q2ResultsEarnings Call Presentation (NYSE:OGN) - Seeking Alpha
Organon jumps despite Q2 revenue dip as revised outlook exceeds consensus - MSN
Earnings call transcript: Organon Q2 2025 beats EPS expectations, stock volatile - Investing.com
Organon Becomes Oversold - Nasdaq
Organon (OGN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Organon & Co. Reports Strong Q2 Earnings, Surpassing ExpectationsNews and Statistics - IndexBox
Organon (OGN) Beats Q2 Earnings and Revenue Estimates - sharewise.com
Organon surpasses expectations with $1.59B revenue in Q2 2025 - grafa.com
Organon's Strategic Path to Financial Stability and Dividend Resumption - AInvest
Organon Q2 2025 slides: Revenue guidance raised amid Women’s Health strength - Investing.com Australia
Organon Q2 Adjusted Earnings, Revenue Fall, Beat Estimates; 2025 Revenue Guidance Raised - MarketScreener
Organon stock jumps after Q2 revenue beat (OGN:NYSE) - Seeking Alpha
Organon (NYSE:OGN) Surprises With Q2 Sales, Stock Soars - Yahoo Finance
Organon shares surge over 8% as Q2 earnings top estimates, raises revenue outlook By Investing.com - Investing.com South Africa
Organon shares surge over 8% as Q2 earnings top estimates, raises revenue outlook - Investing.com India
Organon Co earnings beat by $0.06, revenue topped estimates - Investing.com South Africa
Earnings Snapshot: Organon new revenue outlook beats estimates after strong Q2 (OGN:NYSE) - Seeking Alpha
Organon in charts: Women's Health revenue up ~3% Y/Y in Q2 (NYSE:OGN) - Seeking Alpha
Organon beats Q2 revenue expectations, raises FY guidance - MarketScreener
Earnings Flash (OGN) Organon & Co. Reports Q2 Revenue $1.59B, vs. FactSet Est of $1.55B - MarketScreener
Earnings Flash (OGN) Organon & Co. Posts Q2 Adjusted EPS $1.00 per Share, vs. FactSet Est of $0.95 - MarketScreener
Finanzdaten der Organon Co-Aktie (OGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):